Does TACROLIMUS Cause Product packaging quantity issue? 10 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Product packaging quantity issue have been filed in association with TACROLIMUS (Tacrolimus). This represents 0.0% of all adverse event reports for TACROLIMUS.
10
Reports of Product packaging quantity issue with TACROLIMUS
0.0%
of all TACROLIMUS reports
2
Deaths
1
Hospitalizations
How Dangerous Is Product packaging quantity issue From TACROLIMUS?
Of the 10 reports, 2 (20.0%) resulted in death, 1 (10.0%) required hospitalization.
Is Product packaging quantity issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TACROLIMUS. However, 10 reports have been filed with the FAERS database.
What Other Side Effects Does TACROLIMUS Cause?
Off label use (8,718)
Drug ineffective (6,214)
Product use in unapproved indication (5,057)
Acute kidney injury (4,005)
Transplant rejection (3,526)
Cytomegalovirus infection (3,320)
Covid-19 (3,201)
Drug interaction (2,896)
Diarrhoea (2,854)
Toxicity to various agents (2,845)
What Other Drugs Cause Product packaging quantity issue?
LEUPROLIDE (523)
ALBUTEROL (431)
BUDESONIDE\FORMOTEROL (301)
FENTANYL (286)
BUPRENORPHINE (225)
CYCLOSPORINE (206)
ESTRADIOL (201)
BIMATOPROST (177)
RIVAROXABAN (174)
EXENATIDE (154)
Which TACROLIMUS Alternatives Have Lower Product packaging quantity issue Risk?
TACROLIMUS vs TACROLIMUS\TACROLIMUS ANHYDROUS
TACROLIMUS vs TADALAFIL
TACROLIMUS vs TAFAMIDIS
TACROLIMUS vs TAFAMIDIS MEGLUMINE
TACROLIMUS vs TAFASITAMAB